For high-grade tumors, AYAs diagnosed with triple-negative breast cancer had more than two-fold increased risk of death, whereas AYAs diagnosed with HR+/HER2+ breast cancer experienced approximately half the risk of death, than did AYAs diagnosed with HR+/HER2- breast cancer. This evidence concerns the gene ERBB2 and breast cancer.